Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fomivirsen.

C M Perry1, J A Balfour

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|April 8, 1999
PubMed
Summary
This summary is machine-generated.

Fomivirsen, an antisense oligonucleotide, effectively treats cytomegalovirus retinitis by inhibiting viral replication. Clinical trials show it significantly delays disease progression in patients with AIDS, with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Ophthalmology
  • Virology
  • Pharmacology

Background:

  • Cytomegalovirus (CMV) retinitis is a serious complication, particularly in immunocompromised individuals.
  • Antisense oligonucleotides offer a targeted approach to antiviral therapy.
  • Fomivirsen (ISIS 2922) is an investigational drug targeting CMV replication.

Purpose of the Study:

  • To evaluate the efficacy and safety of fomivirsen for treating CMV retinitis.
  • To determine the pharmacokinetic profile of fomivirsen in retinal tissue.
  • To assess the impact of fomivirsen on the progression of CMV retinitis in patients with AIDS.

Main Methods:

  • Pharmacokinetic studies in monkeys following intravitreal injection.
  • Clinical trials involving patients with CMV retinitis, including those with AIDS.

Related Experiment Videos

  • Assessment of disease progression and adverse events in treated patients.

    • Main Results:

    • Fomivirsen demonstrated a mean maximum retinal concentration at 2 days post-injection in monkeys.
    • The elimination half-life in monkey retina was 78 hours.
    • Fomivirsen significantly delayed CMV retinitis progression in patients with AIDS, with median times to progression of 71 days (early treatment) and 90 days (advanced disease).
    • Common adverse events included increased intraocular pressure and inflammation, generally reversible.

    Conclusions:

    • Fomivirsen is a promising therapeutic agent for CMV retinitis.
    • Intravitreal fomivirsen effectively inhibits CMV replication and delays disease progression.
    • The drug is generally well-tolerated, with manageable ocular side effects.